申请人:Merck Sharp & Dohme Corp.
公开号:US10947205B2
公开(公告)日:2021-03-16
The present invention relates to oxazolidinone compounds of Formula (I):
and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
本发明涉及式(I)的噁唑烷酮化合物:
及其药学上可接受的盐,其中A、E和R1如本文所定义。本发明还涉及包含至少一种本发明噁唑烷酮化合物的组合物。本发明还提供了抑制分枝杆菌细胞生长的方法以及治疗结核分枝杆菌感染的方法,包括施用治疗有效量的本发明噁唑烷酮和/或其药学上可接受的盐,或包含这种化合物和/或盐的组合物。